Abstract:Tumor cells show a higher activity of nucleotide anabolic pathway for uncontrolled proliferation. Triple inhibitions of one‐carbon metabolism and de novo pyrimidine or purine synthesis are achieved with ferrous ions, histidine, and methotrexate (MTX) assembled nanoparticles and fasting‐mimicking diet (FMD). With a 95% lower dose of MTX, the assembled nanoparticles efficiently inhibit the tumor growth together with FMD treatment. The continual growth of tumor cells requires considerable nutrient consumption. Methotrexate (MTX) is used to treat certain types of cancer by blocking the DNA and RNA productions through interfering one‐carbon metabolism and de novo purine and pyrimidine synthesis. However, treatment of MTX may cause many serious adverse effects, which hamper its clinical application. Herein, the authors synthesize ferrous ions, histidine, and MTX assembled nanoparticles (FHM) to deliver MTX at tumor site and enhance the sensitivity of tumor cells to MTX with histidine catabolism. Furthermore, fasting‐mimicking diet (FMD) is applied to intervene in the one‐carbon metabolism and enhance the cytotoxicity of MTX. Meanwhile, FMD treatment can significantly augment the cellular uptake and tumor accumulation of FHM nanoparticles. Due to the triple inhibitions of the one‐carbon metabolism, the proliferation of tumor cells is strongly disturbed, as which is highly replying on DNA and RNA production. Taken together, a 95% lower dose of MTX adopted in combined therapy significantly inhibits the growth of two types of murine tumors without evident systemic toxicity. This strategy may provide a promising nucleotide metabolism‐based nanomedicine for cancer therapy.

Targeting SHMTs and MTHFDs in cancer: attractive opportunity for anti-tumor strategy

A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight

Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential

Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer

MTHFD2 Promotes Tumorigenesis and Metastasis in Lung Adenocarcinoma by Regulating AKT/GSK‐3β/β‐catenin Signalling

Targeting one‐carbon metabolism for cancer immunotherapy

Targeting methionine metabolism in cancer: opportunities and challenges

Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine

Folate-mediated One-Carbon Metabolism: a Targeting Strategy in Cancer Therapy

Impact of One-Carbon Metabolism-Driving Epitranscriptome as a Therapeutic Target for Gastrointestinal Cancer

Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer

Targeting Human MutT Homolog 1（MTH1） for Cancer Eradication:Current Progress and Perspectives

Regulation of Nucleotide Metabolism with Nutrient‐Sensing Nanodrugs for Cancer Therapy

Metabolic Targeting of Cancers: from Molecular Mechanisms to Therapeutic Strategies

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review

Roles of Mitochondrial Serine Hydroxymethyltransferase 2 (SHMT2) in Human Carcinogenesis

Targeting Mitochondrial Metabolic Reprogramming As a Potential Approach for Cancer Therapy

Tracing the Diverse Paths of One-Carbon Metabolism in Cancer and Beyond

Targeting DNA methyltransferases for cancer therapy